ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVO Stock Price » NVO Stock News

Novo Nordisk a S Share News

 Novo-nordisk a/s (denmark) Stock Price
NVO Stock Price
 Novo-nordisk a/s (denmark) Stock Chart
NVO Stock Chart
 Novo-nordisk a/s (denmark) Stock News
NVO Stock News
 Novo-nordisk a/s (denmark) Company Information
NVO Company Information
 Novo-nordisk a/s (denmark) Stock Trades
NVO Stock Trades

Novo Nordisk May Perform Stock Split - Chief Financial Officer

COPENHAGEN -(Dow Jones)- Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) may perform a stock split in the next couple of years, the company's chief financial officer Jesper Brandgaard said Thursday. "We have done several stock splits over the years, when the price has risen to levels that we found too high. With a price of more than $100, it is something we will consider again," Brandgaard said, speaking after the company released its fourth-quarter results. Novo Nordisk, the world's largest maker of insulin, earlier Thursday reported that its net profit rose 19% on the year in the fourth quarter, to 4.69 billion Danish kroner ($829 million). The result was better than expected, helped by strong growth in sales of its GLP-1 diabetes drug Victoza and ultra-long acting insulin Levemir. -By Flemming Emil Hansen and Niclas Rolander, Dow Jones Newswires; +46-8-5451-3102; niclas.rolander@dowjones.com

Stock News for Novo Nordisk a S (NVO)
DateTimeHeadline
06/16/201407:23:04Novo Nordisk Sees 'No Strategic Reason' For Big Mergers -- Update
05/29/201405:56:44Merrion Pharmaceuticals Technology to Be Used in Insulin Tablet...
05/01/201412:30:12EUROPE MARKETS: U.K. Stocks Lead Europe Higher On Quiet May Day
05/01/201405:40:11Novo Nordisk Lowers Sales Forecast
05/01/201405:23:21Novo Nordisk Lowers Sales Forecast on Challenges in U.S. -- Update
04/28/201416:34:00EARNINGS PREVIEW: Novo Nordisk Net Proift Seen Up 6.2%
04/22/201412:38:25EUROPE MARKETS: Drug Stocks Drive European Markets Higher
04/15/201414:40:21Glaxo Wins U.S. Approval for Diabetes Drug
04/15/201414:29:21Glaxo Wins U.S. Approval for Diabetes Treatment Albiglutide
04/14/201411:54:12Novo Nordisk Seeks to Boost Sales of Insulin in U.S., Mexico
03/14/201407:34:03Novo Nordisk Invests DKK550 Million in New R&D Facility
03/07/201408:12:10EUROPE MARKETS: European Stocks Head For Weekly Loss Ahead Of...
02/26/201412:14:17EUROPE MARKETS: European Stocks Pull Back From Six-year High
02/26/201408:48:47EUROPE MARKETS: European Stocks Pull Back From Six-year Highs
02/25/201412:35:45EUROPE MARKETS: Stoxx 600 Extends Gains To Six-year High; Novo...
02/25/201409:00:08Lilly Diabetes Drug Ruled Comparable to Market Leader
01/30/201404:00:09Novo Nordisk Upgrades 2014 Outlook
01/30/201403:22:46Novo Nordisk Upgrades 2014 Outlook, Proposes 25% Dividend Raise
12/27/201312:26:36EUROPE MARKETS: Europe Stocks Charge Higher As Euro Soars
12/23/201315:20:10FDA Approves Treatment for Clotting Disorder

Novo Nordisk a S and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad